QGEN - CIK 0001015820
QIAGEN N.V. trades as QGEN and has a market capitalization of $8.03 B, making it the #1070 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.09B, up 5.7% from the prior year and net income of $424.88M. This page tracks QIAGEN N.V. through 471 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years QIAGEN N.V.'s revenue grew from $1.34B to $2.09B, a compound annual growth rate of 5.1%. Net profit margin expanded from 6.0% to 20.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-08 |
| 6-K | - | 2026-05-08 |
| 6-K | - | 2026-05-01 |
| IRANNOTICE | - | 2026-03-20 |
| 20-F | - | 2026-03-20 |
| SCHEDULE 13G/A | - | 2026-02-10 |
| SCHEDULE 13G | - | 2026-02-06 |
| 6-K | - | 2026-02-06 |
New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow
Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth
The largest companies sharing QIAGEN N.V.'s SEC industry classification (biological products, (no diagnostic substances)).
QIAGEN N.V. (QGEN) has a market capitalization of $8.03 B as of 2026-06-10, ranking #1070 among US-listed companies.
QIAGEN N.V. reported revenue of $2.09B for fiscal year 2025, an increase of 5.7% year over year.
Yes. QIAGEN N.V. reported net income of $424.88M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand